anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention discloses a preparation method for the non-alkaloid part of sophorae tonkinensis, which belongs to the technical field of Chinese medicine. The preparation method is as follows: ethanol is added into water regurgitation extract of the sophorae tonkinensis; insoluble substance is precipitated and filtered; filtrate is condensed and carries out column chromatograph separation by the strong acid cationic resin of crosslinked polystyrene series; the filtrate is eluted by water; eluted water is collected and condensed to ointment; and the ointment is decompressed and dried to obtain the non-alkaloid part. The non-alkaloid part contains carbohydrate, organic acid, phenols and saponin and son on. The preparation process of the invention is easy and quick and the cost of preparation is low. In addition, the quality of various substances of the obtained product is stable and controllable. The non-alkaloid part is applied for reducing enzyme and protecting liver, and offers substance base for seeking more efficient non-alkaloid active components.
Described herein are compounds and their use in the treatment of infections. The compound of formula (I), their derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, solvates, pharmaceutically acceptable salts and pharmaceutical compositions described herein are also useful as Î² -lactamase inhibitors, which restore or enhance the antibiotic spectrum of a suitable antibiotic agent. The compounds of formula (I) act as inhibitors of Î²-lactamases. These compounds restore/potentiate the activities of Î²-lactam antibiotics against carbapenemases. These compounds find use in diagnostic method for detecting Î²-lactamases. Formula (I).
NEW MATERIAL:A 5-fluorouracil derivative shown by the formula (R is acyl group derived from higher fatty acid of hexaene). EXAMPLE:1-(4,7,10,13,16,19-decosahexenoyl)-5-fluorouracil. USE:An inhibitor of blood platelet aggregation, preventive for cancer metastasis, or carcinostatic agent. A dose is 0.1-5g/adult/day, being administered orally, or by venoclysis or by hypodermic injection optionally 1-3 times, dividedly. PREPARATION:For example, a higher fatty acid of hexaene, preferably higher fatty acid having 22-24C is reacted with 5-fluorouracil in the presence of a condensation agent such as 2-chloro-1-methylpyridinium p-toluenesulfonate, etc. to give a compound shown by the formula.
Subject received subcutaneous administration of matching placebo of abatacept once a weeks through the 24 week double blind period. A washout period of MMF for 4 weeks (24 th-28th week) is used to ensure data integrity. Subsequently,subject were administered subcutaneous administration of abatacept 125 mg once every week through the 28-52 week open label period.
Select any area of skin on the body, EXCEPT the extremities below the knee or elbow. The chest is the preferred site. The area should be clean, dry, and hairless. If hair is likely to interfere with system adhesion or removal, it can be clipped but not shaved. Take care to avoid areas with cuts or irritations. Do NOT apply the system immediately after showering or bathing. It is best to wait until you are certain the skin is completely dry.
We aimed to develop and validate a nomogram based on conventional ultrasound (CUS) radiomics model to differentiate radial scar (RS) from invasive ductal carcinoma (IDC) of the breast. In total, 208 patients with histopathologically diagnosed RS or IDC of the breast were enrolled. They were randomly divided in a 7:3 ratio into a training cohort (n = 145) and a validation cohort (n = 63). Overall, 1316 radiomics features were extracted from CUS images. Then a radiomics score was constructed by filtering unstable features and using the maximum relevance minimum redundancy algorithm and the least absolute shrinkage and selection operator logistic regression algorithm. Two models were developed using data from the training cohort: one using clinical and CUS characteristics (Clin + CUS model) and one using clinical information, CUS characteristics, and the radiomics score (radiomics model). The usefulness of nomogram was assessed based on their differentiating ability and clinical utility. Nine features from CUS images were used to build the radiomics score. The radiomics nomogram showed a favorable predictive value for differentiating RS from IDC, with areas under the curve of 0.953 and 0.922 for the training and validation cohorts, respectively. Decision curve analysis indicated that this model outperformed the Clin + CUS model and the radiomics score in terms of clinical usefulness. The results of this study may provide a novel method for noninvasively distinguish RS from IDC.
The patients will receive 6 cycles of CAPOX and PD-1 antibody. TME surgery is scheduled after TNT while a W\&W option can be applied to patients achieving cCR.
An adaptive randomised, double-blind, single-centre, placebo-controlled Phase I study evaluating ECG effects, safety, tolerability and PK of single ascending doses of Modufolin® for Injection, 100 mg in healthy male volunteers. Thirty-three (33) eligible and consenting subjects will be included in 3 cohorts, 11 subjects in each cohort. Within each cohort, subjects will be randomised to receive either placebo (3 subjects) or Modufolin® for Injection, 100 mg (8 subjects). There will be 3 pre-defined ascending dose-levels. Additional dose levels may be considered if recommended by the internal Safety Review cCommittee. There will be an interval between each dose level to allow time for safety data to be analyzed and evaluated by the iSRC. The iSRC will have the choice to decide to escalate the dose as planned, reduce or increase the dose escalation step, repeat the dose, reduce the dose or terminate the study. The total study duration for the subjects will be approximately 5 weeks and there will be in total 3 visits to the clinic. Subjects will be screened for eligibility according to study-specific inclusion/exclusion criteria within 4 weeks prior to start of stud treatment (Visit 1; Screening visit). The subjects will be confined to the research clinic from the evening before dosing (Day -1) until 24 hrs post dose (Days 1 and 2). The subjects should be fasting overnight (8 hrs) before IMP/placebo administration until 4 hrs post-dose. A Follow-up Visit will be performed 5 to 10 days after dose administration of for each cohort.
INTRODUCTION: Residents in NH are more likely to be diagnosed with epilepsy or seizures, which are associated with higher mortality and complicate care. This setting provides unique challenges in the treatment of seizures however, little is known about current management practices in NH. Most studies in the literature concentrate on the use of antiseizure medications (ASMs) but little is known about the management of the acute seizure and clinical guidance is needed to ensure the safety of this vulnerable population. The objective of this study was to survey current practices, identifying knowledge deficits and inform future educational endeavors, including acute seizure action plans (ASAPs).
METHODS: A survey was developed pertaining to a broad spectrum of clinical aspects in the management of acute seizures in NH, distinguishing first time seizures from those in the setting of a known seizure disorder. It was sent to NH medical directors throughout the US and data was gathered from those who had at least one new case of new onset/epilepsy in the last 3 years.
RESULTS: Ninety-one NH directors responded with 52 % having a seizure protocol. Nurses are responsible in the majority of cases for protocol activation. Regardless of the patient's seizure history, rescue medications are given in the majority of cases, oral benzodiazepines, followed by intravenous and then rectal benzodiazepines. Newer intranasal and intramuscular formulations of benzodiazepines were less frequently prescribed. The most commonly prescribed ASM is levetiracetam, followed by lamotrigine, valproic acid and phenytoin. Staff training and in-service education occur infrequently. Respondents thought no-cost seizure education would be highly beneficial.
CONCLUSIONS AND IMPLICATIONS: Only approximately half of NH have protocols for the acute management of seizures. Rescue medications are given regardless of seizure history and often older ASMs are used for long-term management. Our study highlights areas of knowledge deficits and treatment areas for improvement, identifying the need and potential for ASAPs in NHs.
Patients included in the study were randomized into 3 different groups. Group number 1 and 2 got custom made insoles out of EVA (Ethyl Vinyl Acetate) with different hardness 35 and 55 shore respectively. Group nr 3 got prefabricated insole with support of the medial arch and in the forefoot. The top layer was covered with a 2 mm cushioned material, 25 shore, made out of microcellular urethane. All patients were recommended to wear good walking shoes with a semi rigid outer sole and stable heel counter. One and the same technician made the casting and fabricated the insoles as well as delivered the devices. Deliverance occured 2-3 weeks after the first visit.

At deliverance base line measurement was assessed.
FIELD: radio engineering, communication.SUBSTANCE: invention relates to an architecture for networked communication between different medical devices and remote monitoring devices. An interface circuit of each medical device communicates with one of relay modules via a wireless relay network. The relay modules communicate with the remote monitoring devices over an internet-accessible wireless communication network. Each relay module includes a receiver, a first transmitter, a second transmitter and a controller. The controller determines the status of the internet-accessible wireless communication network. When the status indicates that the internet-accessible wireless communication network is accessible to the wireless relay module, the second transmitter is selected for transmitting data from the medical devices. When the internet-accessible wireless communication network is not accessible, the first transmitter is selected for transmitting the data to another wireless relay module.EFFECT: facilitating networking between different medical devices and remote monitoring devices.33 cl, 5 dwg
PROBLEM TO BE SOLVED: To obtain a stabilizer for an denture excellent in easiness of peeling- off from a denture base by compounding a specific oil solution to the denture stabilizer paste using vinyl acetate resin as the base material. SOLUTION: A fluoropolymer based oil solution is compounded to the denture stabilizer paste based on vinyl acetate resin. The fluoropolymers based oil solution are perfluoro organic compounds and are liquid at ordinary temperature, such as perfluoropolyether, perfluorodecalin, perfluorooctane, perfluoropentane, perfluorodecane, etc. The compounding amount is approximately, 1-15wt.%, especially 3-10wt.% preferably. The vinyl acetate resin is approximately compounded in amount of 30-80wt.%, especially 40-70wt.% based on the total weight of the denture stabilizer. This denture stabilizer is capable of commercializing with the use of containers such as an aluminum tube, a laminated tube, a plastic tube, etc.
BACKGROUND: To investigate the individual profile of each SGLT2 (sodium-glucose cotransoporter-2) inhibitor in patients with different backgrounds.
METHODS AND RESULTS: This study included 21 placebo-controlled randomized controlled trials with a total of 96 196 participants, investigating empagliflozin, ertugliflozin, dapagliflozin, canagliflozin, and sotagliflozin. The primary efficacy end point was the composite of cardiovascular death and hospitalizations for heart failure. The secondary efficacy end points were all-cause death, cardiovascular death, hospitalizations for heart failure, kidney disease progression, and acute kidney injury. We conducted subgroup analyses based on the underlying comorbidities, including diabetes and chronic kidney disease. Safety end points were also assessed among SGLT2 inhibitors in the overall cohort. In the overall cohort, there were no significant differences in the primary efficacy outcome among the SGLT2 inhibitors, while empagliflozin (hazard ratio [HR], 0.70 [95% CI, 0.53-0.92]) and dapagliflozin (HR, 0.73 [95% CI, 0.56-0.96]) were associated with lower risk of acute kidney injury than sotagliflozin. The presence or absence of diabetes did not alter the results. In patients with chronic kidney disease, there were no differences in the efficacy outcomes among SGLT2 inhibitors, while in patients without chronic kidney disease, empagliflozin was associated with lower risk of the primary outcome compared with ertugliflozin (HR, 0.77 [95% CI, 0.60-0.98]). For safety outcomes, no significant differences were observed in amputation, urinary tract infection, genital infection, hypoglycemia, and diabetic ketoacidosis.
CONCLUSIONS: The differences in reducing cardiovascular and kidney outcomes as well as safety profiles across SGLT2 inhibitors were not consistently significant, although empagliflozin might be preferred in patients without chronic kidney disease. Further investigations are needed to better understand the mechanism and clinical effectiveness of each SGLT2 inhibitor in certain populations.
Accurate determination of the presence or absence of left atrial appendage (LAA) thrombus has a large impact on the clinical course of patients with atrial fibrillation or ischemic stroke and has large financial implications as well. Misdiagnosing the presence of LAA thrombus can lead to unnecessarily cancelled procedures (cardioversion and atrial fibrillation ablation) and potentially hazardous, unnecessary changes in clinical care (such as prolonged Coumadin anticoagulation). Missing LAA thrombus can result in continuation of cardioversion or atrial fibrillation ablation procedures at a time when there is higher risk of subsequent embolic stroke.

Several of the patients with atrial fibrillation require transesophageal echocardiography (TEE) performed prior to cardioversion or atrial fibrillation ablation procedures. There is opportunity to enroll most of these patients in our proposed study. There has been essentially no work published about the use of echo contrast materials in TEE (other than agitated saline), particularly the use of Optison. Thus, the investigators will be exploring a new field in echocardiography and echo contrast.
This project is designed to address the psychosocial and existential suffering commonly experienced by palliative care patients. Technology-based reminiscence and dignity therapy interventions have been demonstrated to improve well-being and quality of life in older adults (Lazar et al, 2014), although little evidence exists to support the use of these technology-based interventions in a palliative care context.

These technologies may require modification to meet the needs of PEOLC patients that are at risk for delirium, a neuropsychiatric condition characterized by fluctuating disruptions in awareness, focus and cognition (American Psychiatric Association, 2013). Delirium can be experienced by up to 88% of patients at the end of life (Hosie et al., 2013). Moreover, patients in PEOLC settings may also have limited mobility or may be bedbound. Due to the potential for disorientation and reduced physical mobility, patients receiving PEOLC may be unable to fully enjoy an immersive experience using a virtual reality (VR) headset. To reduce the possibility of disorientation that may arise from using a VR headset with 'LIFEView', our research team plans to use the 'LIFEView' prototype software loaded on a laptop and connected to a mobile high-definition 40-42" TV for inpatient PCU and LTC facility use, or to a patient's personal TV within their residence in the community.
PURPOSE:To provide the titled drug containing alpha-tocopherol vitamin A acid ester as an active component, effective for the remedy of dermatic diseases such as ulcus combustionis, perniosis, zona, etc., and having low side effects. CONSTITUTION:An alpha-tocopherol vitamin A acid ester (abbreviated as TOC ester) is used as an active component. There are various external drugs for dermatic diseases, e.g. zinc oxide ointment, an ointment containing adrenocortical hormone, and ointment containing non-steroidal anti-inflammatory agent, an ointment containing antibiotic substance, etc. Although an ointment containing adrenocortical hormone has remarkable remedying effect, it frequently gives severe side effects and often exhibits rebounding phenomenon. On the contrary, the TOC ester gives little side effects in spite of excellent remedying effect to various dermatic diseases (e.g. bedsore, ulcus combustionis, etc.). The content of the TOC is about 0.01-10wt%, preferably about 0.1-5wt%.
Diagnostiskt Centrum (DC), Sweden's first specialized cancer diagnosis center, was established at Kristianstad General Hospital in 2012 as a model for reducing the time taken to diagnose cancer in primary care patients with diffuse, non-organ specific symptoms. If it is successful, the DC model could be rolled out to other areas of Sweden. This study by the Center for Primary Health Care Research in Malmö, Sweden and Regionalt cancercentrum syd will investigate whether the DC process reduces the time from (1) the point when the patient first contacts his/her primary care center with symptoms to (2) the point when he/she is informed about his/her diagnosis (of cancer or another disease). This will be achieved by comparison with matched control patients with suspected cancer who will be referred to Helsingborg General Hospital for further investigation according to existing diagnostic procedures. Various outcome measures will be investigated, and patients' experiences of the DC process will be assessed using a tailored questionnaire. In addition, the DC model will be subjected to health economics analysis.
Subjects will undergo plasmapheresis to generate approximately 1200 mL, that will be manufactured into freeze dried plasma units. After completion of warfarin dosing, approximately 810 mL of freeze dried plasma will be intravenously administered to the subject.
Disclosed are phyllanthus urinaria L. wine capable of clearing heat and calming the liver and a preparation method of the phyllanthus urinaria L. wine. The phyllanthus urinaria L. wine comprises, by weight, 25-35 parts of phyllanthus urinaria L., 15-20 parts of jasminum grandiflorum, 15-20 parts of radix codonopsis lanceolatae, 5-10 parts of pluchea indica, 5-10 parts of purslane speedwell herbs, 5-10 parts of nakedflower beautyberry leaves, 5-10 parts of cardamom, 3-5 parts of agrimony, 3-5 parts of caulis sinomenii, 3-5 parts of fructus nandinae domesticate, 3-5 parts of tetracera asiatica (Lour.) Hoogland, 3-5 parts of trapa incisa var. sieb., 300-400 parts of grain liquor and 400-500 parts of yellow wine. The preparation method of the phyllanthus urinaria L. wine mainly includes the steps of firstly, preparing fine traditional Chinese medicine powder; secondly, preparing medicated wine; thirdly, blending. The phyllanthus urinaria L. wine capable of clearing heat and calming the liver, which combines the traditional Chinese medicinal materials with the yellow wine and the grain liquor reasonably and effectively, has good health care effect and is capable of clearing heat, calming and clearing the liver, improving vision, eliminating infantile malnutrition and checking dysentery to varying degrees when used for treating main disease syndromes such as spleen qi deficiency, epersalgia and asthenic disease.
OBJECTIVES: Understanding speech in noise (SIN) is the dominant complaint of individuals with hearing loss. For decades, the default test of speech perception in routine audiologic assessment has been monosyllabic word recognition in quiet (WRQ), which does not directly address patient concerns, leading some to advocate that measures of SIN should be integrated into routine practice. However, very little is known with regard to how SIN abilities are affected by different types of hearing loss. Here, we examine performance on clinical measures of WRQ and SIN in a large patient base consisting of a variety of hearing loss types, including conductive (CHL), mixed (MHL), and sensorineural (SNHL) losses.
DESIGN: In a retrospective study, we examined data from 5593 patients (51% female) who underwent audiometric assessment at the Stanford Ear Institute. All individuals completed pure-tone audiometry, and speech perception testing of monaural WRQ, and monaural QuickSIN. Patient ages ranged from 18 to 104 years (average = 57). The average age in years for the different classifications of hearing loss was 51.1 (NH), 48.5 (CHL), 64.2 (MHL), and 68.5 (SNHL), respectively. Generalized linear mixed-effect models and quartile regression were used to determine the relationship between hearing loss type and severity for the different speech-recognition outcome measures.
RESULTS: Patients with CHL had similar performance to patients with normal hearing on both WRQ and QuickSIN, regardless of the hearing loss severity. In patients with MHL or SNHL, WRQ scores remained largely excellent with increasing hearing loss until the loss was moderately severe or worse. In contrast, QuickSIN signal to noise ratio (SNR) losses showed an orderly systematic decrease as the degree of hearing loss became more severe. This effect scaled with the data, with threshold-QuickSIN relationships absent for CHL, and becoming increasingly stronger for MHL and strongest in patients with SNHL. However, the variability in these data suggests that only 57% of the variance in WRQ scores, and 50% of the variance in QuickSIN SNR losses, could be accounted for by the audiometric thresholds. Patients who would not be differentiated by WRQ scores are shown to be potentially differentiable by SIN scores.
CONCLUSIONS: In this data set, conductive hearing loss had little effect on WRQ scores or QuickSIN SNR losses. However, for patients with MHL or SNHL, speech perception abilities decreased as the severity of the hearing loss increased. In these data, QuickSIN SNR losses showed deficits in performance with degrees of hearing loss that yielded largely excellent WRQ scores. However, the considerable variability in the data suggests that even after classifying patients according to their type of hearing loss, hearing thresholds only account for a portion of the variance in speech perception abilities, particularly in noise. These results are consistent with the idea that variables such as cochlear health and aging add explanatory power over audibility alone.
The invention discloses a blueberry branch flavone and an extracting method thereof. The blueberry branch flavone is a blueberry extract, and the active ingredient of the blueberry branch flavone is a blueberry branch ethanol extract. The blueberry branch ethanol extract is prepared by crushing blueberry branches, mixing the crushed blueberry branches and an aqueous solution of ethanol, performing flash extraction on a mixture, centrifuging the treated mixture and collecting supernate liquid to obtain the blueberry branch ethanol extract. In the crushing step, the mesh of a screen to be used is 50-100 meshes; the mass percentage concentration of the aqueous solution of ethanol is 40-80%; the use amount ratio of the crushed blueberry branches to the aqueous solution of ethanol is 1 g to 20-60 ml. In the flash extraction step, the voltage of a flash extractor is 30-110 V, and the extraction time is 30-150s, preferably 120s. In the centrifuging step, the rotation speed is 3000-8000 r/min, the centrifugal radius is 5-15 cm, and the centrifuging time is 5-20 minutes. The extracting method has the characteristics of being high in speed and high in efficiency.